248 related articles for article (PubMed ID: 22328940)
1. TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia.
Pérez C; Martínez-Calle N; Martín-Subero JI; Segura V; Delabesse E; Fernandez-Mercado M; Garate L; Alvarez S; Rifon J; Varea S; Boultwood J; Wainscoat JS; Cruz Cigudosa J; Calasanz MJ; Cross NC; Prósper F; Agirre X
PLoS One; 2012; 7(2):e31605. PubMed ID: 22328940
[TBL] [Abstract][Full Text] [Related]
2. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia.
Yamazaki J; Taby R; Vasanthakumar A; Macrae T; Ostler KR; Shen L; Kantarjian HM; Estecio MR; Jelinek J; Godley LA; Issa JP
Epigenetics; 2012 Feb; 7(2):201-7. PubMed ID: 22395470
[TBL] [Abstract][Full Text] [Related]
3. TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia.
Yamazaki J; Jelinek J; Lu Y; Cesaroni M; Madzo J; Neumann F; He R; Taby R; Vasanthakumar A; Macrae T; Ostler KR; Kantarjian HM; Liang S; Estecio MR; Godley LA; Issa JP
Cancer Res; 2015 Jul; 75(14):2833-43. PubMed ID: 25972343
[TBL] [Abstract][Full Text] [Related]
4. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.
Jankowska AM; Makishima H; Tiu RV; Szpurka H; Huang Y; Traina F; Visconte V; Sugimoto Y; Prince C; O'Keefe C; Hsi ED; List A; Sekeres MA; Rao A; McDevitt MA; Maciejewski JP
Blood; 2011 Oct; 118(14):3932-41. PubMed ID: 21828135
[TBL] [Abstract][Full Text] [Related]
5. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance.
Grossmann V; Kohlmann A; Eder C; Haferlach C; Kern W; Cross NC; Haferlach T; Schnittger S
Leukemia; 2011 May; 25(5):877-9. PubMed ID: 21339759
[No Abstract] [Full Text] [Related]
6. TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.
Martínez-Avilés L; Besses C; Álvarez-Larrán A; Torres E; Serrano S; Bellosillo B
Ann Hematol; 2012 Apr; 91(4):533-41. PubMed ID: 21904853
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
[TBL] [Abstract][Full Text] [Related]
8. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
Figueroa ME; Abdel-Wahab O; Lu C; Ward PS; Patel J; Shih A; Li Y; Bhagwat N; Vasanthakumar A; Fernandez HF; Tallman MS; Sun Z; Wolniak K; Peeters JK; Liu W; Choe SE; Fantin VR; Paietta E; Löwenberg B; Licht JD; Godley LA; Delwel R; Valk PJ; Thompson CB; Levine RL; Melnick A
Cancer Cell; 2010 Dec; 18(6):553-67. PubMed ID: 21130701
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features.
Palomo L; Malinverni R; Cabezón M; Xicoy B; Arnan M; Coll R; Pomares H; García O; Fuster-Tormo F; Grau J; Feliu E; Solé F; Buschbeck M; Zamora L
Epigenetics; 2018; 13(1):8-18. PubMed ID: 29160764
[TBL] [Abstract][Full Text] [Related]
10. Genetics of the myeloproliferative neoplasms.
Abdel-Wahab O
Curr Opin Hematol; 2011 Mar; 18(2):117-23. PubMed ID: 21307773
[TBL] [Abstract][Full Text] [Related]
11. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
Smith AE; Mohamedali AM; Kulasekararaj A; Lim Z; Gäken J; Lea NC; Przychodzen B; Mian SA; Nasser EE; Shooter C; Westwood NB; Strupp C; Gattermann N; Maciejewski JP; Germing U; Mufti GJ
Blood; 2010 Nov; 116(19):3923-32. PubMed ID: 20693430
[TBL] [Abstract][Full Text] [Related]
12. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.
Brecqueville M; Rey J; Bertucci F; Coppin E; Finetti P; Carbuccia N; Cervera N; Gelsi-Boyer V; Arnoulet C; Gisserot O; Verrot D; Slama B; Vey N; Mozziconacci MJ; Birnbaum D; Murati A
Genes Chromosomes Cancer; 2012 Aug; 51(8):743-55. PubMed ID: 22489043
[TBL] [Abstract][Full Text] [Related]
13. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.
Coltro G; Mangaonkar AA; Lasho TL; Finke CM; Pophali P; Carr R; Gangat N; Binder M; Pardanani A; Fernandez-Zapico M; Robertson KD; Bosi A; Droin N; Vannucchi AM; Tefferi A; Hunter A; Padron E; Solary E; Patnaik MM
Leukemia; 2020 May; 34(5):1407-1421. PubMed ID: 31836856
[TBL] [Abstract][Full Text] [Related]
14. Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia.
Wei Y; Kanagal-Shamanna R; Zheng H; Bao N; Lockyer PP; Class CA; Darbaniyan F; Lu Y; Lin K; Yang H; Montalban-Bravo G; Ganan-Gomez I; Soltysiak KA; Do KA; Colla S; Garcia-Manero G
Leukemia; 2022 Aug; 36(8):2097-2107. PubMed ID: 35697791
[TBL] [Abstract][Full Text] [Related]
15. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.
Kohlmann A; Grossmann V; Klein HU; Schindela S; Weiss T; Kazak B; Dicker F; Schnittger S; Dugas M; Kern W; Haferlach C; Haferlach T
J Clin Oncol; 2010 Aug; 28(24):3858-65. PubMed ID: 20644105
[TBL] [Abstract][Full Text] [Related]
16. TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations.
Kim YH; Pierscianek D; Mittelbronn M; Vital A; Mariani L; Hasselblatt M; Ohgaki H
J Clin Pathol; 2011 Oct; 64(10):850-2. PubMed ID: 21690245
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of the interaction between ASXL1 and TET2 gene mutations in patients with chronic myelomonocytic leukemia: a meta-analysis.
Zhao W; Zhang C; Li Y; Li Y; Liu Y; Sun X; Liu M; Shao R
Hematology; 2022 Dec; 27(1):367-378. PubMed ID: 35306971
[TBL] [Abstract][Full Text] [Related]
18. 5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia.
Ahn JS; Kim HJ; Kim YK; Lee SS; Ahn SY; Jung SH; Yang DH; Lee JJ; Park HJ; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Michael S; Minden MD; Kim DD
Oncotarget; 2017 Jan; 8(5):8305-8314. PubMed ID: 28039446
[TBL] [Abstract][Full Text] [Related]
19. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia.
Rampal R; Alkalin A; Madzo J; Vasanthakumar A; Pronier E; Patel J; Li Y; Ahn J; Abdel-Wahab O; Shih A; Lu C; Ward PS; Tsai JJ; Hricik T; Tosello V; Tallman JE; Zhao X; Daniels D; Dai Q; Ciminio L; Aifantis I; He C; Fuks F; Tallman MS; Ferrando A; Nimer S; Paietta E; Thompson CB; Licht JD; Mason CE; Godley LA; Melnick A; Figueroa ME; Levine RL
Cell Rep; 2014 Dec; 9(5):1841-1855. PubMed ID: 25482556
[TBL] [Abstract][Full Text] [Related]
20. TET proteins and 5-methylcytosine oxidation in hematological cancers.
Ko M; An J; Pastor WA; Koralov SB; Rajewsky K; Rao A
Immunol Rev; 2015 Jan; 263(1):6-21. PubMed ID: 25510268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
